當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院2區(qū) JCRQ1 期刊介紹(非官網(wǎng))

Frontiers In ImmunologySCIE

國(guó)際簡(jiǎn)稱：FRONT IMMUNOL 參考譯名：免疫學(xué)前沿

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1664-3224; E-ISSN：1664-3224; 是否OA：開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：SWITZERLAND; 出版商：Frontiers Media S.A.; 出版語言：English; 出版周期：1 issue/year; 出版年份：2010; 研究方向：IMMUNOLOGY

評(píng)價(jià)信息：: 影響因子：5.7; H-index：84; CiteScore指數(shù)：9.8; SJR指數(shù)：1.868; SNIP指數(shù)：1.193

發(fā)文數(shù)據(jù)：: Gold OA文章占比：99.67%; 研究類文章占比：71.28%; 年發(fā)文量：5971; 自引率：0.1095...; 開源占比：0.9946; 出版撤稿占比：0.0006...; 出版國(guó)人文章占比：0.11; OA被引用占比：1

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Frontiers In Immunology期刊介紹

Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. Field Chief Editor Luigi Daniele Notarangelo is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.

Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.

期刊簡(jiǎn)介Frontiers In Immunology期刊介紹

《Frontiers In Immunology》自2010出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間： 14 Weeks
國(guó)際TOP期刊
醫(yī)學(xué)
IMMUNOLOGY
SCIE
中科院2區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Frontiers In Immunology Cite Score數(shù)據(jù)

CiteScore：9.8
SJR：1.868
SNIP：1.193

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Immunology and Allergy	Q1	52 / 233	77%
大類：Medicine 小類：Immunology	Q1	58 / 236	75%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Frontiers In Immunology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	IMMUNOLOGY 免疫學(xué)	2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Frontiers In Immunology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q1	38 / 181	79.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q1	43 / 181	76.52%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA3036
CHINA MAINLAND1649
GERMANY (FED REP GER)1306
England910
Italy761
France731
Netherlands576
Spain456
Australia418
Canada412

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
Author: Zhu, Youwen; Liu, Kun; Qin, Qun; Zhu, Hong

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1044678
2、Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China
Author: Zhao, Dan-Tong; Yan, Hui-Ping; Liao, Hui-Yu; Liu, Yan-Min; Han, Ying; Zhang, Hai-Ping; Zhang, Wei-Ming; Huang, Chun-Yang; Liu, Xiu-Hong; Lou, Jin-Li; Zhao, Yan

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1098076
3、The altered metabolites contributed by dysbiosis of gut microbiota are associated with microbial translocation and immune activation during HIV infection
Author: Zhang, Yu; Xie, Zhiman; Zhou, Jie; Li, Yanjun; Ning, Chuanyi; Su, Qisi; Ye, Li; Ai, Sufang; Lai, Jingzhen; Pan, Peijiang; Liu, Ningmei; Liao, Yanyan; Su, Qijian; Li, Zhuoxin; Liang, Hao; Cui, Ping; Huang, Jiegang

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1020822
4、Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection
Author: Zhang, Lu; Jiang, Tingting; Yang, Ying; Deng, Wen; Lu, Huihui; Wang, Shiyu; Liu, Ruyu; Chang, Min; Wu, Shuling; Gao, Yuanjiao; Hao, Hongxiao; Shen, Ge; Xu, Mengjiao; Chen, Xiaoxue; Hu, Leiping; Yang, Liu; Bi, Xiaoyue; Lin, Yanjie; Lu, Yao; Jiang, Yuyong; Li, Minghui; Xie, Yao

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1112234
5、Depressive symptoms predict longitudinal changes of chronic inflammation at the transition to adulthood
Author: Zhai, Shuang; Qu, Yang; Zhang, Dan; Li, Tingting; Xie, Yang; Wu, Xiaoyan; Zou, Liwei; Yang, Yajuan; Tao, Fangbiao; Tao, Shuman

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1036739
6、Granulocytic myeloid-derived suppressor cells increase infection risk via the IDO/IL-10 pathway in patients with hepatitis B virus-related liver failure
Author: Yu, Xueping; Sun, Jian; Yang, Feifei; Mao, Richeng; Shen, Zhiqing; Ren, Lan; Yuan, Songhua; He, Qian; Zhang, Linxia; Yang, Yu; Ding, Xiangqing; He, Yongquan; Zhu, Haoxiang; Shen, Zhongliang; Zhu, Mengqi; Qiu, Chao; Su, Zhijun; Zhang, Jiming

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.966514
7、Combination of transcriptional biomarkers and clinical parameters for early prediction of sepsis indued acute respiratory distress syndrome
Author: Yao, Ren-Qi; Shen, Zong; Ma, Qi-Min; Ling, Ping; Wei, Chen-Ru; Zheng, Li-Yu; Duan, Yu; Li, Wei; Zhu, Feng; Sun, Yu; Wu, Guo-Sheng

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1084568
8、m6A eraser FTO modulates autophagy by targeting SQSTM1/P62 in the prevention of canagliflozin against renal fibrosis
Author: Yang, Youjing; Li, Qianmin; Ling, Yi; Leng, Linxin; Ma, Yu; Xue, Lian; Lu, Guoyuan; Ding, Yue; Li, Jianzhong; Tao, Shasha

Journal: FRONTIERS IN IMMUNOLOGY. 2023; Vol. 13, Issue , pp. -. DOI: 10.3389/fimmu.2022.1094556